Condition (MeSH)
Familial Mediterranean Fever
ClinicalTrials.gov lists 59 trials for Familial Mediterranean Fever or a narrower condition beneath it. Sheba Medical Center has the most among industry and government lead sponsors, with 5.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
59 of the 59 trials are tagged with Familial Mediterranean Fever itself; the rest are tagged with a narrower condition beneath it.
When did Familial Mediterranean Fever trials start? (20)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 11
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 7 |
| 2025 | 11 |
| 2024 | 7 |
| 2023 | 3 |
| 2022 | 5 |
| 2021 | 4 |
| 2020 | 1 |
| 2019 | 1 |
| 2018 | 6 |
| 2014 | 1 |
Showing 10 of 20 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 10 trials starting in 2026 and about 11 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Familial Mediterranean Fever trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 8 |
| Phase 2/3 | 1 |
| Phase 3 | 2 |
| Phase 4 | 2 |
| Not applicable | 14 |
| Observational | 31 |
How many Familial Mediterranean Fever trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 11 |
| Recruiting | 11 |
| Enrolling by invitation | 2 |
| Active, not recruiting | 3 |
| Completed | 18 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Familial Mediterranean Fever trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Sheba Medical Center | 5 |
| Novartis Pharmaceuticals | 3 |
| Bursa City Hospital | 2 |
| R-Pharm International, LLC | 2 |
| Aristea Therapeutics, Inc. | 1 |
Which drugs are being tested for Familial Mediterranean Fever? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| RPH - 104 | 2 |
| Rilonacept | 2 |
| RIST4721 | 1 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Anakinra alone (stages 2b/3) | 3 |
| Colchicines | 2 |
| NC-503 (Anti-amyloidotic (AA) Agent) | 1 |
| Canakinumab, ACZ885 | 1 |
| Probiotic | 1 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Familial Mediterranean Fever trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Hospitalization for FMF attack | 4 | 1 |
| Renal Calculi | 2 | 1 |
| Blood and lymphatic system disorders - Other (Macrophage Activation Syndrome) | 1 | 1 |
| Cerebrospinal fluid leakage | 1 | 1 |
| Joint infection-mycobacterium | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Familial Mediterranean Fever? (67)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Predictors of proteinuria, amyloidosis and kidney failure in familial Mediterranean fever: data from the International AIDA Network Registry. | Rheumatology (Oxford, England) | 2025 | Yes |
| An Update on Familial Mediterranean Fever. | International journal of molecular sciences | 2023 | Yes |
| Does Age at Onset Affect the Clinical Presentation of Familial Mediterranean Fever in Children? | Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases | 2022 | Yes |
| Familial Mediterranean Fever and Diet: A Narrative Review of the Scientific Literature. | Nutrients | 2022 | Yes |
| Anakinra-Associated Amyloidosis. | JAMA dermatology | 2022 | Yes |
Showing 5 of 67 publications.
Prevalence (18)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Familial Mediterranean fever | Point prevalence | 1-9 / 1 000 000 | Japan | Not stated | Unspecified |
| Familial Mediterranean fever | Point prevalence | >1 / 1000 | Armenia | Not stated | Unspecified |
| Familial Mediterranean fever | Point prevalence | 1-9 / 1 000 000 | Japan | Not stated | Exact |
| Familial Mediterranean fever | Point prevalence | 1-9 / 100 000 | Sweden | Not stated | Unspecified |
| Familial Mediterranean fever | Point prevalence | 1-9 / 100 000 | Sweden | Not stated | Exact |
Showing 5 of 18 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Familial Mediterranean fever | 342 | Exact | Orphadata Science knowledge files, Product 1 |
| Familial Mediterranean fever | 342 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.